In vitro AD models for efficacy evaluation of neurotoxicity and neuroinflammation induced by Aβ oligomers (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR011.04 / W1; Pres time: Nov 14, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "Trontinemab and Lecanemab demonstrated therapeutic efficacy in enhancing immune clearance and inhibiting Aβ accumulation, respectively. Future studies will expand this system to test combination therapies, aiming to accelerate screening of novel disease-modifying treatments."
Preclinical • Alzheimer's Disease • CNS Disorders • CD68
|
|
L. CHEN1; L. ZHU1; J. XU1; S. ZHANG1; P. YE1; R. FENG2
|